Boehringer Ingelheim Animal Health USA Inc. v Intervet International B.V. [2022] FCAFC 88Date:Court:Judges:18 May...
Intervet inventive step in a veterinary injectable formulation holds on appeal from patent office
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Multiple interlocutory decisions in long-running mining systems infringement cases
Australian Mud Company Pty Ltd v Globaltech Corporation Pty Ltd & Ors (No 2) [2022] FCA 88(experimental evidence)...
Experimental Use Exception Clarified
Jusand Nominees Pty Ltd v Rattlejack Innovations Pty Ltd [2022] FCA 540 Date:Court:Judge:16 May 2022Federal Court of...
Medicinal Cannabis in Australia | Part 5: Making therapeutic claims: advertising and labelling of medicinal cannabis products
Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such...
Pearce IP BioBlast® w/e 13 May 2022
04 May 22 | Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal...
Too late to challenge amendments once infringement proceedings commenced
Illinois Tool Works Inc v Airco Fasteners Pty Ltd [2022] FCA 495 Date:Court:Judge:5 May 2022Federal Court of...
When supply of a staple commercial product is not infringement
Hood v Down Under Enterprises International Pty Ltd [2022] FCAFC 69Date:Court:Judges:4 May 2022Full Federal Court of...
Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways
Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not...
Pearce IP BioBlast® w/e 06 May 2022
29 Apr 22 | Merck announced that the EC has approved Keytruda® (pembrolizumab) in combination with chemotherapy (with...
Prototype demonstrations invalidate competitor’s patent
Rakman International Pty Ltd v Boss Fire & Safety Pty Ltd [2022] FCA 464Date:Court:Judge:29 April 2022Federal...
Psychedelic Medicines Part 1
Patenting known and new chemical entities
Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately...
Medicinal Cannabis in Australia | Part 1: Available Products
Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal...
Pearce IP BioBlast® w/e 29 April 2022
21 Apr 22 | AU | Australia’s TGA granted orphan drug designation to Roche’s glofitamab. The TGA also provided...
Pearce IP BioBlast® w/e 22 April 2022
14 Apr 22 | CA | BIOJAMP announced the launch of SIMLANDI™/AVT02 (high-concentration, low volume, citrate-free...
Pharmacia’s Dynastat patent expires before injunction ordered; but validity challenge means section 19 certification is still issued
We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the...
Artificial intelligence cannot be a patent inventor
Commissioner of Patents v Thaler [2022] FCAFC 62Date:Court:Judges:13 April 2022Full Court of the Federal Court of...